TR47 decreases capillary vascular VEGF-induced permeability in the skin. VEGF-induced extravasation of Evans blue in the skin was determined in immune competent SKH1-E mice. (A) The experimental time line for the in vivo VEGF-induced vascular leakage model and administration of peptides. (B) Photographs for Evans blue extravasation in the skin of 2 representative mice that received the P3R_L (left) or P3K_L (right) peptide after subcutaneous injection with VEGF (3 left arrows) or with bovine serum albumin (BSA) control (2 right arrows). (C) Pseudo-colored heat map display of Evans blue extravasation quantified by the Odyssey near infrared imager at 700 nm. P3R_L- (left) or P3K_L- (right) treated mice were injected subcutaneously with VEGF (3 left arrows) or with BSA control (2 right arrows). (D) Quantification of in vivo VEGF-induced vascular leakage for mice treated with phosphate-buffered saline (PBS) control, P3R_L (125 μg), or P3K_L (125 μg) peptide. Data are also shown for BSA-treated control mice that received PBS, P3R_L, or P3K_L but no VEGF. (B-C) Representative experiments. (D) Data points represent the mean ± SEM (n ≥ 8). Asterisk denotes a statistically significant difference (P < .05).